Forwarded from Clinical Notes (Salah Mansour)
1-s2.0-S0168822721005453-main1.pdf
4.4 MB
1-s2.0-S0168822721005453-main1.pdf
👍2
Forwarded from مكتبة دار الثقافة العصرية
critical care essential therapeutics للدكتور خالد محمد علي كتاب شامل ومفصل للأدوية الضرورية بالرعاية الحرجة ويعتبر هاذا الكتاب هو رفيق أساسي لجميع فرق العناية المركزة؛ الفرق الطبية وفرق الطوارئ والجراحة التي تتعامل مع الأمراض الحرجة والمنقذة للحياة وعلاجاتها الأساسية. الكتاب غني بجميع الأدوية الأساسية والتطبيقات السريرية المستخدمة في إدارة الأمراض الحرجة والطارئة المختلفة والإجراءات الحرجة الأساسية التي يتم شرحها في مناقشات بسيطة للغاية ورسوم توضيحية للملصقات
❤9👍3
Forwarded from مكتبة دار الثقافة العصرية
فهرس كتابCritical Care Essential Thrapeutics.pdf
15.5 MB
❤11🤔3
❤18👍5👏4🔥2
🛑Managing Portal Vein Thrombosis in Patients with Cirrhosis
🛑Who should receive anticoagulation:
✅A patient with intestinal ischemia requires emergent anticoagulation and should be managed by a multidisciplinary team if available.
✅A patient with a recent PVT (<6 months) that is >50% occlusive or involves the main portal vein or mesenteric vessels (particularly if more than one vascular bed is involved), a patient who is a liver transplant candidate, or a patient in whom thrombus has progressed.
🛑Who should not receive anticoagulation:
✅A patient with recent thrombosis (<6 months) involving the intrahepatic portal vein branches or with <50% occlusion of the main portal vein, splenic vein, or mesenteric veins. (However, follow-up computed tomography or magnetic resonance imaging every 3 months is required, and anticoagulation should be started if symptoms develop, the patient becomes a liver transplant candidate, or clot progression occurs.)
✅Vitamin K antagonists, low-molecular-weight heparin (LMWH), and direct-acting oral anticoagulants all can be used in patients with Child-Pugh class A/B cirrhosis. Only LMWH should be used in patients with class C cirrhosis
✅Patients who are receiving anticoagulation should undergo CT or MRI every 3 months, and anticoagulation should be continued if partial improvement is seen.
#NEJM watch guidelines 2025
🛑Who should receive anticoagulation:
✅A patient with intestinal ischemia requires emergent anticoagulation and should be managed by a multidisciplinary team if available.
✅A patient with a recent PVT (<6 months) that is >50% occlusive or involves the main portal vein or mesenteric vessels (particularly if more than one vascular bed is involved), a patient who is a liver transplant candidate, or a patient in whom thrombus has progressed.
🛑Who should not receive anticoagulation:
✅A patient with recent thrombosis (<6 months) involving the intrahepatic portal vein branches or with <50% occlusion of the main portal vein, splenic vein, or mesenteric veins. (However, follow-up computed tomography or magnetic resonance imaging every 3 months is required, and anticoagulation should be started if symptoms develop, the patient becomes a liver transplant candidate, or clot progression occurs.)
✅Vitamin K antagonists, low-molecular-weight heparin (LMWH), and direct-acting oral anticoagulants all can be used in patients with Child-Pugh class A/B cirrhosis. Only LMWH should be used in patients with class C cirrhosis
✅Patients who are receiving anticoagulation should undergo CT or MRI every 3 months, and anticoagulation should be continued if partial improvement is seen.
#NEJM watch guidelines 2025
👍11🔥2❤1
🛑Should not fast
✅Poorly controlled hypertension (as defined by your specialist)
✅ Recent acute coronary syndrome / myocardial infarction (<6 weeks)
✅ Hypertrophic Cardiomyopathy with obstruction
✅ Severe valvular disease
✅ Severe heart failure without advanced features
✅ Poorly controlled arrhythmias (as defined by your specialist)
✅ High risk of fatal arrhythmias (e.g. inherited arrhythmic syndromes, arrhythmogenic cardiomyopathy)
✅ Implantable cardioverter defibrillator +/- cardiac resynchronisation therapy
✅Poorly controlled hypertension (as defined by your specialist)
✅ Recent acute coronary syndrome / myocardial infarction (<6 weeks)
✅ Hypertrophic Cardiomyopathy with obstruction
✅ Severe valvular disease
✅ Severe heart failure without advanced features
✅ Poorly controlled arrhythmias (as defined by your specialist)
✅ High risk of fatal arrhythmias (e.g. inherited arrhythmic syndromes, arrhythmogenic cardiomyopathy)
✅ Implantable cardioverter defibrillator +/- cardiac resynchronisation therapy
👍5
بالنسبه للاستاتين
اذا كان لم يستخدم او ماشي من قبل ب جرعه قليل او متوسط ف يجب إعطائه نعطيه جرعه عاليه
High intensity
وبتوصيه اقل ممكن نضيف دواء اخر
Non intensity
اعادة المتابعه بعد 6-8 اسابيع
اما اذا كان بالجرعه العاليه هنا فيه عدة خيارات
اذا اقل من 55 نستمر بنفس الجرعه اما اذا كان ما بين 56 -69 فهنا نضيف دواء اخر من غير العائله لكن التوصيه هنا اقل كانت class 2a
اما اذا كثر من 70 هنا نضيف دواء اخر ايضا لكن التوصيه هنا كانت
Class 1
اذا كان لم يستخدم او ماشي من قبل ب جرعه قليل او متوسط ف يجب إعطائه نعطيه جرعه عاليه
High intensity
وبتوصيه اقل ممكن نضيف دواء اخر
Non intensity
اعادة المتابعه بعد 6-8 اسابيع
اما اذا كان بالجرعه العاليه هنا فيه عدة خيارات
اذا اقل من 55 نستمر بنفس الجرعه اما اذا كان ما بين 56 -69 فهنا نضيف دواء اخر من غير العائله لكن التوصيه هنا اقل كانت class 2a
اما اذا كثر من 70 هنا نضيف دواء اخر ايضا لكن التوصيه هنا كانت
Class 1
👍8❤3
سلسله تحديثات جديده في الجايدلاين الامريكي 2025
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes:
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes:
👍5❤3
برنامج
Micromedx
تم دمجه كل البرامج وأصبح برنامج واحد
اسم المستخدم والرمز نفس بعض ذا
Commhealth🧸
سوف انزل فيديو توضيح لتفعيلة🧸
Micromedx
تم دمجه كل البرامج وأصبح برنامج واحد
اسم المستخدم والرمز نفس بعض ذا
Commhealth
سوف انزل فيديو توضيح لتفعيلة
Please open Telegram to view this post
VIEW IN TELEGRAM
👏8❤4🔥2
This media is not supported in your browser
VIEW IN TELEGRAM
طريقه تفعيل برنامج Micromedx
قم ب نسخ كود التفعيل الذي يضهر لك وليس الي فعلت انا
واستخدم اسم المستخدم وكلمة السر
Commhealth
قم ب نسخ كود التفعيل الذي يضهر لك وليس الي فعلت انا
واستخدم اسم المستخدم وكلمة السر
Commhealth
❤23🔥5👍4🎉3🥰2
#remember
✅Hypokalemia is a particularly important risk factor that can promote digoxin-induced arrhythmias even if the digoxin concentration is thought to be within the "therapeutic" range
#UPTODATE2025
✅Hypokalemia is a particularly important risk factor that can promote digoxin-induced arrhythmias even if the digoxin concentration is thought to be within the "therapeutic" range
#UPTODATE2025
👍14❤3
🛑Medications that may cause "pill esophagitis
✅Bisphosphonates (oral)
✅Clindamycin
✅Doxycycline
✅Erythromycin
✅Iron supplements
✅NSAIDs
✅Potassium chloride
✅Quinidine
✅Tetracycline
✅Trimethoprim-sulfamethoxazole
#UPTODATE2025
✅Bisphosphonates (oral)
✅Clindamycin
✅Doxycycline
✅Erythromycin
✅Iron supplements
✅NSAIDs
✅Potassium chloride
✅Quinidine
✅Tetracycline
✅Trimethoprim-sulfamethoxazole
#UPTODATE2025
🔥11👍7❤3💯1
Clinical Notes
🛑Medications that may cause "pill esophagitis ✅Bisphosphonates (oral) ✅Clindamycin ✅Doxycycline ✅Erythromycin ✅Iron supplements ✅NSAIDs ✅Potassium chloride ✅Quinidine ✅Tetracycline ✅Trimethoprim-sulfamethoxazole #UPTODATE2025
✅Pill-induced:
Ulcerations are usually singular and deep, occurring at points of stasis (especially near the carina), with sparing of the distal esophagus
Ulcerations are usually singular and deep, occurring at points of stasis (especially near the carina), with sparing of the distal esophagus
👍8❤6👏1
#New
🛑Updated KDIGO Guidelines for Chronic Kidney Disease
🛑 Interventions to Delay CKD Progression and Manage Complications
🉐Prescribe sodium–glucose cotransporter-2 (SGLT-2) inhibitors in adults with CKD and either of the following:
✅Type 2 diabetes and eGFR ≥20 mL/minute/1.73 m2
✅No diabetes and eGFR ≥20 mL/minute/1.73 m2 and ACR ≥200 mg/g; OR eGFR 20–45 mL/minute/1.73 m2 and ACR <200 mg/g; OR heart failure (with or without proteinuria)
🉐Prescribe statin or statin-plus-ezetimibe combination therapy
✅patients who are not receiving dialysis and are 50 or older;
✅OR are 18 to 49 with concurrent diabetes, heart disease, prior stroke, or 10-year risk for major adverse coronary events >10%.
#NEJM2025
🛑Updated KDIGO Guidelines for Chronic Kidney Disease
🛑 Interventions to Delay CKD Progression and Manage Complications
🉐Prescribe sodium–glucose cotransporter-2 (SGLT-2) inhibitors in adults with CKD and either of the following:
✅Type 2 diabetes and eGFR ≥20 mL/minute/1.73 m2
✅No diabetes and eGFR ≥20 mL/minute/1.73 m2 and ACR ≥200 mg/g; OR eGFR 20–45 mL/minute/1.73 m2 and ACR <200 mg/g; OR heart failure (with or without proteinuria)
🉐Prescribe statin or statin-plus-ezetimibe combination therapy
✅patients who are not receiving dialysis and are 50 or older;
✅OR are 18 to 49 with concurrent diabetes, heart disease, prior stroke, or 10-year risk for major adverse coronary events >10%.
#NEJM2025
❤15👍4🔥2